AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17199766 — intervention group
Group type: COMPARATOR
Intervention: Skin temperature differential at baseline
Number of subjects: 332
Study 14615738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A therapy (administered intramuscularly on days 1, 3, and 7)
Number of subjects: 40
Study 14615738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 14615738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A therapy
Number of subjects: 40
Study 10979640 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily for 12 weeks
Number of subjects: 96
Study 10979640 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg daily for 12 weeks
Number of subjects: 96
Study 10979640 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy + long-acting nitrates, digoxin, aspirin, and furosemide
Number of subjects: 96
Study 8637340 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous standard heparin (5000 IU every 12 h) until hospital discharge or for a maximum of 3 weeks
Number of subjects: 5776
Study 8637340 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment (control group)
Number of subjects: 5776
Study 1593573 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms/day for one week)
Number of subjects: 13
Study 1593573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1593573 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 13
Study 30528641 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (concurrent training: power training + high-intensity interval training, HIIT)
Number of subjects: 20
Study 30528641 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 30069910 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1204
Study 26376112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-PRO (1.5 g milk protein/100 mL)
Number of subjects: 15
Study 26376112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lo-PRO (0.76 g milk protein/100 mL)
Number of subjects: 15
Study 26376112 — intervention group
Group type: COMPARATOR
Intervention: CONT (0 g milk protein/100 mL)
Number of subjects: 15
Study 25249697 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress (Trier Social Stress Test)
Number of subjects: 28
Study 22337460 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcrylate (iso amyl 2‐cyanoacrylate)
Number of subjects: 60
Study 22337460 — intervention group
Group type: COMPARATOR
Intervention: 6‐0 Prolene (sutures)
Number of subjects: 60
Study 25885382 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 10 mg/kg
Number of subjects: 70
Study 25885382 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 20 mg/kg
Number of subjects: 70
Study 16928714 — intervention group
Group type: EXPERIMENTAL
Intervention: Management pathway to improve early delivery of appropriate antibiotics, implemented using a multifaceted strategy.
Number of subjects: 0
Study 16928714 — intervention group
Group type: COMPARATOR
Intervention: Control site (no specific intervention mentioned).
Number of subjects: 0
Study 16928714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the intervention.
Number of subjects: 0
Study 16928714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of preventing death.
Number of subjects: 0
Study 16119522 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine protein to osmolality ratio (Uprot/Uosm)
Number of subjects: 150
Study 16119522 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine protein to creatinine ratio (Up/Ucr)
Number of subjects: 150
Study 16119522 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine specimens (Uprot/Uosm and Up/Ucr)
Number of subjects: 150
Study 12108850 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 0
Study 12108850 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 0
Study 12024361 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention strategies for neural tube defects
Number of subjects: 0
Study 7547016 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 618
Study 7547016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 7547016 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol and Placebo
Number of subjects: 618
Study 1689512 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rinse consisting of hydrocortisone, nystatin, tetracycline, and diphenhydramine
Number of subjects: 0
Study 1689512 — intervention group
Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 0
Study 7368106 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (2 gm the day before operation and 1.2 gm daily for 5 days after operation)
Number of subjects: 56
Study 7368106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosage as metronidazole)
Number of subjects: 56
Study 7368106 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 56
Study 7368106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 28273681 — intervention group
Group type: COMPARATOR
Intervention: Glazing group (control)
Number of subjects: 52
Study 28273681 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding-glazing group
Number of subjects: 52
Study 28273681 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding-D+Z group
Number of subjects: 52
Study 28273681 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding-OptraFine group
Number of subjects: 52
Study 29065875 — intervention group
Group type: EXPERIMENTAL
Intervention: Examiner scores and feedback for Asian students
Number of subjects: 0
Study 29065875 — intervention group
Group type: EXPERIMENTAL
Intervention: Response times to Asian-stereotypical vs neutral words
Number of subjects: 0
Study 29065875 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition rates for real vs invented stereotype-consistent vs stereotype-inconsistent phrases
Number of subjects: 0
Study 25673013 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐Only
Number of subjects: 141429
Study 25673013 — intervention group
Group type: COMPARATOR
Intervention: Phone/Web
Number of subjects: 141429
Study 25673013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 141429
Study 24956042 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (150-300 mg/day)
Number of subjects: 193
Study 24956042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 24956042 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 193
Study 22609540 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus mixing-point masking
Number of subjects: 48
Study 22609540 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus total masking
Number of subjects: 48
Study 22609540 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 48
Study 19340676 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT+naltrexone
Number of subjects: 298
Study 19340676 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 298
Study 17707752 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (three 5‐min cycles of right upper limb ischaemia, inflated to 200 mm Hg)
Number of subjects: 57
Study 17707752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 57
Study 15631969 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer training
Number of subjects: 180
Study 15631969 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge of computers
Number of subjects: 180
Study 15631969 — intervention group
Group type: EXPERIMENTAL
Intervention: Good attitude and utilization habits
Number of subjects: 180
Study 15631969 — intervention group
Group type: EXPERIMENTAL
Intervention: Good computer knowledge among students and doctors
Number of subjects: 180
Study 15631969 — intervention group
Group type: EXPERIMENTAL
Intervention: Good utilization habits and attitudes
Number of subjects: 180
Study 11520780 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 1 microg/kg
Number of subjects: 59
Study 11520780 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 3 microg/kg
Number of subjects: 59
Study 11520780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9576164 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2.0 mg for ≤50 kg, 2.5 mg for 50-80 kg, 3.0 mg for ≥80 kg)
Number of subjects: 200
Study 7835449 — intervention group
Group type: EXPERIMENTAL
Intervention: 9/0 elastic polypropylene sutures
Number of subjects: 52
Study 7835449 — intervention group
Group type: COMPARATOR
Intervention: 10/0 nylon sutures
Number of subjects: 52
Study 3170985 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract prepared from whole mite culture (WMC)
Number of subjects: 24
Study 3170985 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract from purified mite bodies (MB)
Number of subjects: 24
Study 31969138 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Errors (ME) observed in patients
Number of subjects: 311
Study 31969138 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of Medication Errors
Number of subjects: 311
Study 31969138 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug associated with ME
Number of subjects: 311
Study 31969138 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 311
Study 30086277 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 15 mg
Number of subjects: 159
Study 30086277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 28228148 — intervention group
Group type: EXPERIMENTAL
Intervention: 25mg melatonin
Number of subjects: 240
Study 28228148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 25840503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 16
Study 25840503 — intervention group
Group type: COMPARATOR
Intervention: Continued Moderate Training (CON) for 12 weeks
Number of subjects: 16
Study 24968543 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 92
Study 24968543 — intervention group
Group type: COMPARATOR
Intervention: Low‐molecular weight heparin (LMWH)
Number of subjects: 92
Study 21328002 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally implantable hearing devices (Esteem, Envoy system)
Number of subjects: 10
Study 21328002 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted device (Esteem, Envoy system)
Number of subjects: 10
Study 21328002 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative temporal bone CT scan anatomy
Number of subjects: 10
Study 19605530 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study 19605530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17019627 — intervention group
Group type: EXPERIMENTAL
Intervention: DTkid training
Number of subjects: 0
Study 17019627 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of DTkid training trials
Number of subjects: 0
Study 17019627 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study 16336486 — intervention group
Group type: EXPERIMENTAL
Intervention: BSW (patient-rated global assessment of treatment benefit)
Number of subjects: 3
Study 16336486 — intervention group
Group type: EXPERIMENTAL
Intervention: BSW
Number of subjects: 3
Study 16336486 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients dissatisfied with treatment
Number of subjects: 3
Study 16336486 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients unwilling to continue treatment
Number of subjects: 3
Study 16336486 — intervention group
Group type: EXPERIMENTAL
Intervention: BSW measures
Number of subjects: 3
Study 12587378 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and concurrent chemoradiotherapy
Number of subjects: 281
Study 12587378 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 281
Study 10099057 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador (twice 0.1 mg and once 2.5 mg)
Number of subjects: 7
Study 10099057 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador (2.5 mg)
Number of subjects: 7
Study 7855376 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged inflation (13.5 +/- 3.3 min) at 6 atmospheres using an autoperfusion catheter
Number of subjects: 153
Study 7855376 — intervention group
Group type: COMPARATOR
Intervention: Standard inflations (3.1 +/- 1.6 min) using conventional catheters
Number of subjects: 153
Study 2679374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (400 mg i.v. or per os every 8 or 12 h for 7 to 180 days)
Number of subjects: 103
Study 2679374 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g i.v. every 8 h or 1 g intramuscularly every 8 h for 7 to 56 days)
Number of subjects: 103
Study 2679374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 103
Study 2679374 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 103
Study 941075 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous peritoneal dialysis
Number of subjects: 300
Study 941075 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 300
Study 941075 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective early identification of severe pancreatitis
Number of subjects: 300
Study 941075 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management improvements
Number of subjects: 300
Study 31159727 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab
Number of subjects: 16
Study 31159727 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab
Number of subjects: 16
Study 28793042 — intervention group
Group type: EXPERIMENTAL
Intervention: MP‐TLH (total laparoscopic hysterectomy with 3 abdominal incisions)
Number of subjects: 42
Study 28793042 — intervention group
Group type: COMPARATOR
Intervention: SP‐TLH (total laparoscopic hysterectomy with a single umbilical incision)
Number of subjects: 42
Study 26042336 — intervention group
Group type: EXPERIMENTAL
Intervention: TURis bipolar vaporization
Number of subjects: 84
Study 26042336 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 84
Study 23265980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem (medroxyprogesterone acetate and estradiol cypionate)
Number of subjects: 15
Study 21623465 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention for diabetes management
Number of subjects: 2169
Study 21623465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2169
Study 18461430 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI with double transseptal puncture
Number of subjects: 31
Study 16009588 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg, two inhalations; total doses 1280/36 microg)
Number of subjects: 104
Study 16009588 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 microg x eight inhalations; total doses 1600 microg)
Number of subjects: 104
Study 16009588 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (control)
Number of subjects: 104
Study 16009588 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 104
Study 12915742 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐134a beclomethasone dipropionate (HFA‐BDP) 400 microg b.i.d.
Number of subjects: 41
Study 12915742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 375 microg b.i.d.
Number of subjects: 41
Study 12915742 — intervention group
Group type: COMPARATOR
Intervention: Control (washout period)
Number of subjects: 41
Study 10881757 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gown
Number of subjects: 69
Study 10881757 — intervention group
Group type: COMPARATOR
Intervention: Control drape
Number of subjects: 69
Study 8998256 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine or Diltiazem
Number of subjects: 11
Study 2238665 — intervention group
Group type: COMPARATOR
Intervention: Neomycin and erythromycin (1 g each) administered preoperatively to Group B patients.
Number of subjects: 31
Study 2238665 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin or cefotetan (2 g intravenously) administered preoperatively to Group C patients.
Number of subjects: 31
Study 2238665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral and parenteral antibiotics in Group D patients.
Number of subjects: 31
Study 678048 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadyl acetate
Number of subjects: 28
Study 678048 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 28
Study 678048 — intervention group
Group type: COMPARATOR
Intervention: Nondrug users
Number of subjects: 28
Study 31727428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt (350-mm2 Baerveldt glaucoma implant)
Number of subjects: 242
Study 31727428 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes)
Number of subjects: 242
Study 31727428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt
Number of subjects: 242
Study 31727428 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 242
Study 31053788 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 10% Human Phenotype Ontology (HPO) IDs based on information content
Number of subjects: 50
Study 31053788 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 30% Human Phenotype Ontology (HPO) IDs based on information content
Number of subjects: 50
Study 31053788 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 50% Human Phenotype Ontology (HPO) IDs based on information content
Number of subjects: 50
Study 31053788 — intervention group
Group type: COMPARATOR
Intervention: Randomly chosen Human Phenotype Ontology (HPO) IDs
Number of subjects: 50
Study 28785810 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint + paraffin treatment (five consecutive days a week for 3 weeks)
Number of subjects: 70
Study 28785810 — intervention group
Group type: COMPARATOR
Intervention: Splint treatment (during the night and day time as much as possible for 3 weeks)
Number of subjects: 70
Study 23749244 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid every 6 months over 3 years
Number of subjects: 63
Study 22363056 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy
Number of subjects: 455
Study 19952403 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg) injected slowly via the vein after anesthesia and maintained at 0.5 mg/(kg.h) until the end of CPB
Number of subjects: 40
Study 19952403 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactated solution (control group)
Number of subjects: 40
Study 17264717 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in oxygen (8 l/min) via a prefilled circuit, end‐tidal sevoflurane maintained at 4%
Number of subjects: 40
Study 17264717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity technique with similar anesthesia protocol as Group A
Number of subjects: 40
Study 17264717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation with similar anesthesia protocol as Group A
Number of subjects: 40
Study 17264717 — intervention group
Group type: EXPERIMENTAL
Intervention: End‐tidal sevoflurane maintained at 2% with similar anesthesia protocol as Group A
Number of subjects: 40
Study 15117576 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardian Continuous Monitoring System (Alert group)
Number of subjects: 71
Study 15117576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 12516956 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine
Number of subjects: 1077
Study 9619190 — intervention group
Group type: EXPERIMENTAL
Intervention: Young subjects (18-30 years)
Number of subjects: 32
Study 9619190 — intervention group
Group type: COMPARATOR
Intervention: Older subjects (62-79 years)
Number of subjects: 32
Study 9619190 — intervention group
Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 32
Study 7710345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative choledochoscopic electrohydraulic lithotripsy
Number of subjects: 10
Study 7710345 — intervention group
Group type: COMPARATOR
Intervention: Transduodenal sphincteroplasty
Number of subjects: 10
Study 2717651 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil (Efamol) for 8 weeks
Number of subjects: 0
Study 2717651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 519632 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyldopa
Number of subjects: 0
Study 519632 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubidium
Number of subjects: 0
Study 519632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan‐benserazide
Number of subjects: 0
Study 30964526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU/d; n=251)
Number of subjects: 417
Study 30964526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=166)
Number of subjects: 417
Study 28911070 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1)
Number of subjects: 414
Study 28911070 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CET/RT (Arm B2)
Number of subjects: 414
Study 28911070 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT or CET/RT
Number of subjects: 414
Study 28911070 — intervention group
Group type: COMPARATOR
Intervention: Concomitant treatment alone with CCRT (Arm A1)
Number of subjects: 414
Study 28911070 — intervention group
Group type: COMPARATOR
Intervention: Concomitant treatment alone with CET/RT (Arm A2)
Number of subjects: 414